Marker therapeutics announces $16.1 million private placement

Strategic financing supports clinical advancement in phase 1 apollo study investigating mt-601 in patients with lymphoma who relapsed after anti-cd19 car-t cells strategic financing supports clinical advancement in phase 1 apollo study investigating mt-601 in patients with lymphoma who relapsed after anti-cd19 car-t cells
CAR Ratings Summary
CAR Quant Ranking